Insurance companies currently do not have to offer the RSV vaccine for free, placing the onus on patients and parents to cover its cost.
As the rollout of the Respiratory Syncytial Virus vaccine gains momentum, concerns are emerging regarding accessibility and potential costs for vulnerable populations.
RSV season, which began this month and runs through April, claimed the lives of 300 children and 10,000 older adults last year alone, according to the CDC.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
RSV drug shortage prompts CDC to adjust recommendationsNicoletta Lanese is the health channel editor at Live Science and was previously a news editor and staff writer at the site. She holds a graduate certificate in science communication from UC Santa Cruz and degrees in neuroscience and dance from the University of Florida.
Read more »
RSV cases at Children’s Health reach highest point this yearRSV cases at Children’s Health reached a 2023 high last week as the year’s cold and flu season begins to pick up steam.
Read more »
RSV vaccine shortage for babies: What parents need to know to keep infants safeThe CDC has announced limited availability of Sanofi immunization Beyfortus for RSV prevention in infants. Here's what parents should know to keep babies safe.
Read more »
Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer RSV vaccine lags GSK’s as head-to-head competition underway
Read more »
Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer (PFE.N), which dominated COVID vaccine sales, now finds itself looking up at GSK (GSK.L), whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer.
Read more »
Infant RSV Antibody Shortage: Here Are The CDC Recommended AlternativesI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Read more »